Heart conduction disease
MONDO:0000992A disease that has its basis in the disruption of the heart's electrical conduction system.
Also known as: cardiac conduction disease, cardiac conduction disorder, conduction disease of heart, disease of cardiac conduction, disorder of cardiac conduction
178 clinical trials for this condition and its sub-types, 7 tagged with Heart conduction disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Heart conduction disease
-
Atrioventricular block 57 trials · 63 incl. sub-types
4 sub-types
- Third-degree atrioventricular block 10 trials
- Second-degree atrioventricular block 2 trials · 7 incl. sub-types Sub-types →
- Congenital heart block 2 trials
- First-degree atrioventricular block 1 trial
-
Sinoatrial node disorder 5 trials · 22 incl. sub-types
1 sub-type
- Sick sinus syndrome 22 trials Sub-types →
-
Progressive familial heart block 0 trials · 19 incl. sub-types
3 sub-types
-
Brugada syndrome 10 trials
9 sub-types
- Brugada syndrome 1 0 trials
- Brugada syndrome 2 0 trials
- Brugada syndrome 3 0 trials
- Brugada syndrome 4 0 trials
- Brugada syndrome 5 0 trials
- Brugada syndrome 6 0 trials
- Brugada syndrome 7 0 trials
- Brugada syndrome 8 0 trials
- Brugada syndrome 9 0 trials
-
Catecholaminergic polymorphic ventricular tachycardia 9 trials · 10 incl. sub-types
7 sub-types
- Catecholaminergic polymorphic ventricular tachycardia 1 2 trials
- Catecholaminergic polymorphic ventricular tachycardia 2 1 trial
- Catecholaminergic polymorphic ventricular tachycardia 3 0 trials
- Catecholaminergic polymorphic ventricular tachycardia 4 0 trials
- Catecholaminergic polymorphic ventricular tachycardia 5 0 trials
- Long QT syndrome 16 0 trials
- Ventricular tachycardia, catecholaminergic polymorphic 6 0 trials
-
Wolff-Parkinson-White syndrome 3 trials
-
Short QT syndrome 1 trial
4 sub-types
- Short QT syndrome 7 0 trials
- Short QT syndrome type 1 0 trials
- Short QT syndrome type 2 0 trials
- Short QT syndrome type 3 0 trials
-
Sinoatrial block 0 trials
Most studied deeper sub-types
-
Could a pacemaker also treat high blood pressure? a new device aims to do both.
Disease control Stopped earlyThis trial tests a special pacemaker called the Moderato System in people who need a pacemaker and have high blood pressure that is hard to control with medication. The device is implanted like a regular pacemaker and may help lower blood pressure by adjusting the heart's pacing.…
Sponsor: BackBeat Medical Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a pacemaker tame stubborn high blood pressure?
Disease control Stopped earlyThis trial tests a special pacemaker-like device, the Moderato System, designed to lower blood pressure in people who have resistant hypertension and already need a dual-chamber pacemaker. Participants are randomly assigned to have the device's blood-pressure-lowering feature tur…
Sponsor: BackBeat Medical Inc • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Heart drug study halted early: what we know
Disease control Stopped earlyThis study tested an experimental drug called CRD-4730 in people with a rare inherited heart rhythm disorder (CPVT) that can cause dangerous fast heartbeats. Seven adults received two different doses of the drug and a placebo to check safety and how the body processes it. The stu…
Phase 2 • Sponsor: Cardurion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Hope dashed: drug trial for Post-COVID racing heart stopped early
Disease control Stopped earlyThis study tested a drug called IgPro20 (HIZENTRA) to see if it could help people with post-COVID POTS, a condition that causes a rapid heart rate and dizziness when standing. The trial was stopped early after enrolling only 16 adults. The goal was to see if the drug could reduce…
Phase 3 • Sponsor: CSL Behring • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Experimental drug for Post-COVID POTS study halted early
Disease control Stopped earlyThis study looked at the long-term safety of efgartigimod in adults with post-COVID postural orthostatic tachycardia syndrome (POTS), a condition causing rapid heart rate and dizziness upon standing. The trial was an open-label extension for people who completed a previous study.…
Phase 2 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC